Publicaciones en las que colabora con Carlos Manuel González (27)

2022

  1. Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI Project

    Reumatologia Clinica, Vol. 18, Núm. 2, pp. 114-123

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  2. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

  3. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice

    Reumatologia Clinica, Vol. 14, Núm. 6, pp. 346-359

2017

  1. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2016

  1. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

2013

  1. Comparación de 2 estrategias de derivación en el diagnóstico de la espondiloartritis axial en España. Estudio RADAR

    Reumatologia Clinica, Vol. 9, Núm. 6, pp. 348-352

2011

  1. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)

    Rheumatology, Vol. 50, Núm. 10, pp. 1828-1837

  2. Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis

    Journal of Rheumatology, Vol. 38, Núm. 5, pp. 893-897

2010

  1. Fibromyalgia in patients with ankylosing spondylitis: Prevalence and utility of the measures of activity, function and radiological damage

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 6 SUPPL. 63

2007

  1. Disease pattern of spondyloarthropathies in Spain: Description of the first national registry (REGISPONSER) - Extended report

    Rheumatology, Vol. 46, Núm. 8, pp. 1309-1315

2005

  1. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

    Rheumatology, Vol. 44, Núm. 12, pp. 1555-1558

2002

  1. Clinical features and predictive factors in psoriatic arthritis-related uveitis

    Seminars in Arthritis and Rheumatism, Vol. 31, Núm. 4, pp. 264-270

  2. Psoriatic spondyloarthropathy: A comparative study between HLA-B27 positive and HLA-B27 negative disease

    Seminars in Arthritis and Rheumatism, Vol. 31, Núm. 6, pp. 413-418

2001

  1. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate

    Clinical and Experimental Rheumatology, Vol. 19, Núm. 6, pp. 727-730